This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2025 Zacks Investment Research | 101 N Wacker Drive, Floor 15, Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.64% per year. These returns cover a period from January 1, 1988 through August 4, 2025. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
biotechs: Archive
RXRX Q2 Loss Wider Than Expected, Revenues Rise Y/Y, Stock Down
by Zacks Equity Research
Recursion Pharmaceuticals stock drops as Q2 loss widens and pipeline shake-up continues, despite revenues boost from Sanofi milestone.
CRMDNegative Net Change ARVNNegative Net Change IMCRNegative Net Change RXRXNegative Net Change
artificial-intelligence biotechnology biotechs earnings medical oncology-screening pharmaceuticals
Ultragenyx's Q2 Loss Narrower Than Expected, Revenues Rise Y/Y
by Zacks Equity Research
RARE posts a narrower Q2 loss and 13% revenue growth as demand rises across all four marketed rare disease drugs.
REGNNegative Net Change RARENegative Net Change ARVNNegative Net Change IMCRNegative Net Change
biotechnology biotechs earnings medical pharmaceuticals
Bayer Beats on Q2 Earnings and Sales, Raises '25 Adjusted Sales View
by Zacks Equity Research
BAYRY beats on Q2 earnings and raises 2025 sales outlook (on a currency-adjusted basis) as pharma growth offsets currency and Xarelto headwinds.
REGNNegative Net Change JNJNegative Net Change BAYRYNegative Net Change
biotechnology biotechs earnings medical pharmaceuticals
JAZZ Stock Down on Wider-Than-Expected Q2 Loss, '25 Sales View Cut
by Zacks Equity Research
Jazz shares slide as Q2 loss widens on Chimerix charge, with 2025 sales outlook trimmed despite higher EPS guidance.
JAZZNegative Net Change CRMDNegative Net Change GMABNegative Net Change IMCRNegative Net Change
biotechs earnings medical
BMY Stock Trades Near 52-Week Low: Time to Buy or Sell?
by Ekta Bagri
BMY trims earnings outlook despite revenue beat and upbeat drug sales, sending shares to a 52-week low before a rebound. We recommend investors to stay on the sidelines for now.
BMYNegative Net Change PFENegative Net Change BNTXNegative Net Change
biotechnology biotechs earnings-report medical pharmaceuticals
ZTS Q2 Earnings & Revenues Beat Estimates, '25 Outlook Raised
by Zacks Equity Research
Zoetis posts better-than-expected Q2 results with rising sales of pet medicines, boosting its 2025 outlook.
ZTSNegative Net Change CRMDNegative Net Change ARVNNegative Net Change IMCRNegative Net Change
biotechnology biotechs earnings medical pharmaceuticals
TGTX Down as Q2 Earnings Miss Mark, Briumvi Sales Drive Top Line
by Zacks Equity Research
TG Therapeutics slides 18% as second-quarter earnings fall short despite a 92% revenue jump fueled by surging Briumvi sales.
TGTXNegative Net Change CRMDNegative Net Change ARVNNegative Net Change IMCRNegative Net Change
biotechs earnings
CRSP Stock Down on Huge Q2 Loss, Focus on Increasing Casgevy Adoption
by Zacks Equity Research
CRISPR Therapeutics posts a wider second-quarter loss tied to Sirius deal costs, while Casgevy adoption gains momentum across global markets.
VRTXNegative Net Change CRSPPositive Net Change GMABNegative Net Change IMCRNegative Net Change
biotechs crispr earnings gene-editing gene-therapy medical
AXSM Q2 Loss Narrower Than Expected, Auvelity Drives Revenues Y/Y
by Zacks Equity Research
Axsome posts narrower second-quarter loss and 72% revenue surge, driven by strong Auvelity sales.
JAZZNegative Net Change CRMDNegative Net Change AXSMNegative Net Change IMCRNegative Net Change
biotechs earnings
VRTX Q2 Earnings Beat, Stock Down as Pain Drug Misses Study Goal
by Zacks Equity Research
Vertex beats second-quarter earnings and revenue estimates, but shares slide as pain drug VX-993 misses study goal.
VRTXNegative Net Change CRMDNegative Net Change CRSPPositive Net Change IMCRNegative Net Change
biotechs earnings
BioMarin Beats on Q2 Earnings & Sales, Stock Gains on Raised '25 View
by Zacks Equity Research
BMRN's Q2 earnings surge 50% on strong Voxzogo and enzyme therapy sales, prompting a raised 2025 revenue and EPS outlook.
SNYNegative Net Change BMRNNegative Net Change GMABNegative Net Change IMCRNegative Net Change
biotechs earnings medical pharmaceuticals
Catalyst Pharmaceutics to Report Q2 Earnings: What's in the Cards?
by Zacks Equity Research
CPRX gears up to report Q2 results as Firdapse sales rise, Agamree grows, and Fycompa faces a post-patent dip.
CPRXNegative Net Change ACADNegative Net Change DNLINegative Net Change
biotechnology biotechs earnings medical pharmaceuticals
Cabometyx Sales Miss Mark in Q2: What Does This Mean for EXEL Stock?
by Ekta Bagri
EXEL rides on strong Cabometyx demand in RCC and NET, but Q2 sales miss and rising competition cloud the outlook.
BMYNegative Net Change PFENegative Net Change MRKNegative Net Change EXELPositive Net Change
biotechnology biotechs medical pharmaceuticals
KRYS Q2 Earnings and Sales Top Estimates, Stock Down on Q3 Outlook
by Zacks Equity Research
Krystal Biotech tops Q2 estimates with strong Vyjuvek sales, but shares fall 14% on weak Q3 revenue guidance.
BAYRYNegative Net Change CRMDNegative Net Change KRYSNegative Net Change IMCRNegative Net Change
biotechnology biotechs earnings medical pharmaceuticals
Recursion Pharmaceuticals to Report Q2 Earnings: What's in the Cards?
by Zacks Equity Research
RXRX eyes Q2 earnings beat despite past misses, with a refocused pipeline and new data updates on key drug candidates.
ZTSNegative Net Change ACADNegative Net Change RXRXNegative Net Change
biotechnology biotechs earnings medical oncology-screening pharmaceuticals
Novo Nordisk Before Q2 Earnings: How Should Investors Play the Stock?
by Ahan Chakraborty
NVO's second-quarter revenues are expected to have been driven by its sales of diabetes and obesity care products, Wegovy, Ozempic and Rybelsus.
NVOPositive Net Change LLYNegative Net Change AMGNNegative Net Change VKTXNegative Net Change
biotechnology biotechs earnings-preview medical pharmaceuticals
Will These 5 Pharma, Biotech Bigwigs Surpass Q2 Earnings Forecasts?
by Zacks Equity Research
Let's look at five pharma and biotech companies, PFE, LLY, AMGN, GILD and NVO, which are scheduled to release their second-quarter 2025 results this week.
PFENegative Net Change NVOPositive Net Change LLYNegative Net Change AMGNNegative Net Change GILDNegative Net Change
biotechs pharmaceuticals
Sarepta to Report Q2 Earnings: What's in Store for the Stock?
by Zacks Equity Research
SRPT's Q2 report, set to arrive Aug. 6, is likely to have Elevidys updates, restructuring plans and sales outlook in sharp investor focus.
SRPTNegative Net Change ARWRNo Net Change ACADNegative Net Change GMABNegative Net Change
biotechs earnings medical pharmaceuticals
How Did Skyrizi and Rinvoq Sales Contribute to AbbVie's Q2 Results?
by Sundeep Ganoria
AbbVie's Q2 results show Skyrizi and Rinvoq powering growth, offsetting Humira declines and lifting 2025 sales outlook.
JNJNegative Net Change LLYNegative Net Change ABBVNegative Net Change
biotechs earnings medical pharmaceuticals
GILD Likely to Beat on Q2 Earnings: Buy, Sell or Hold the Stock?
by Zacks Equity Research
GILD eyes Q2 gains as demand for HIV drugs holds strong despite pricing pressures and cell therapy headwinds. We recommend investors to wait and watch for now.
GSKNegative Net Change MRKNegative Net Change GILDNegative Net Change
biotechnology biotechs earnings medical pharmaceuticals
MRNA Beats on Q2 Earnings & Sales, Stock Down on Lowered Sales View
by Zacks Equity Research
MRNA tops Q2 estimates with a narrower loss and revenue beat, but the stock slips after trimming 2025 sales guidance.
PFENegative Net Change MRKNegative Net Change MRNANegative Net Change BNTXNegative Net Change
biotechs medical messenger-rna pharmaceuticals vaccines
ALNY Q2 Earnings Top Estimates on Higher Amvuttra Revenues, Stock Up
by Zacks Equity Research
Alnylam stock jumps 15% after a surprise Q2 profit, driven by soaring Amvuttra sales and raised 2025 revenue guidance.
REGNNegative Net Change ALNYNegative Net Change NVSNegative Net Change RHHBYNegative Net Change
biotechnology biotechs earnings medical pharmaceuticals
FOLD Q2 Earnings Miss Mark, Revenues Beat on Higher Product Sales
by Zacks Equity Research
Amicus misses second-quarter earnings estimates but beats the same for revenues, driven by strong sales of Galafold and Pombiliti + Opfolda.
FOLDNegative Net Change CRMDNegative Net Change ARVNNegative Net Change IMCRNegative Net Change
biotechs earnings
Zoetis Gears Up to Report Q2 Earnings: Here's What to Expect
by Zacks Equity Research
ZTS eyes an earnings beat as companion animal drugs like Simparica Trio and Apoquel are expected to drive Q2 revenue gains.
ZTSNegative Net Change EXASNegative Net Change BNTXNegative Net Change
biotechnology biotechs earnings medical pharmaceuticals
Regeneron Stock Rises on Q2 Earnings and Sales Beat, Eylea HD Sales Up
by Zacks Equity Research
REGN stock up as Q2 EPS jumps 12% on strong Eylea HD and Dupixent profits, beating revenue and earnings estimates.
REGNNegative Net Change SNYNegative Net Change BAYRYNegative Net Change
biotechnology biotechs earnings medical pharmaceuticals